(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 41. The pharmaceutical composition according to Claim 40, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

Claim 42. The pharmaceutical composition according to Claim 40, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI.

Claim 43. A method of inhibiting the effects mediated by PKA type Iα isozyme comprising administering to subject in need of said inhibition, a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler,

so as to inhibit the localization of PKA type Iα isozyme with T cell receptor/CD3 complexes.

Claim 44. The method according to Claim 43, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

Claim 45. A method of treating a subject afflicted with an immunosuppressive disease, comprising administering to said subject a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 46. The method of Claim 45, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type Iα isozyme ($RI\alpha_2C_2$).

Claim 47. The method of Claim 46, wherein said cAMP antagonist is a thio-substituted cAMP analog, wherein said thio-substituted cAMP analog is an equatorial diastereomer of 3',5'-cyclic adenosine monophosphorothioate (Rp-cAMPS), and wherein said thio-substituted cAMP analog binds to an RIα subunit of said isozyme and acts as a selective or specific antagonist of said isozyme.

Claim 48. The method of Claim 47, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS, Rp-piperidino-cAMPS, and Rp-8-Cl-cAMPS.

Claim 49. The method of Claim 48, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claim 50. The method of Claim 45, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI. --